2'-deoxy-[5']xanthylic acid | 5187-90-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: 2'-deoxy-[5']xanthylic acid
• 英文别名: 2'-Deoxy-xanthosine-5'-monophosphate；[(2R,3S,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 5187-90-6
• 化学式: C₁₀H₁₃N₄O₈P
• 分子量: 348.209
• InChiKey: RTWWRSBEQVIVBY-KVQBGUIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Measuring method and composition using kinase
  申请人：ASAHI KASEI PHARMA CORPORATION

  公开号：US10472665B2

  公开（公告）日：2019-11-12

  The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.

  本发明提供了一种激酶正向反应底物、其磷酸化产物及其前体中至少一种的测量方法，包括以下步骤：(1)通过使至少一种激酶、该激酶的第一核苷酸辅酶和具有与第一核苷酸辅酶不同核苷分子的第二核苷酸辅酶与样品接触，进行酶循环反应；(3) 根据检测到的信号变化，计算样品中含有的激酶正向反应底物和/或磷酸化产物的量。
• NOVEL MEASUREMENT METHOD USING KINASE, AND COMPOSITION
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP3199639B1

  公开（公告）日：2020-12-30
• Oligomer-Nucleoside Phosphate Conjugates
  申请人：Ren Zhongxu

  公开号：US20100286084A1

  公开（公告）日：2010-11-11

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
• OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES
  申请人：NEKTAR THERAPEUTICS

  公开号：US20140371168A1

  公开（公告）日：2014-12-18

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.
• NOVEL MEASURING METHOD AND COMPOSITION USING KINASE
  申请人：ASAHI KASEI PHARMA CORPORATION

  公开号：US20170306389A1

  公开（公告）日：2017-10-26

  The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.